v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)
 3 Months Ended
Jul. 31, 2026
Jul. 31, 2025
Cash flows from operating activities:    
Net loss $ (5,081,191) $ (8,360,096)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on re-fair value of warrants 0 (106,000)
Adjustment from accrued liabilities to warrant liabilities 0 (469,000)
Stock-based compensation - options 0 60,492
Unrealized loss on marketable equity securities 154,548 104,463
Change in fair value of warrant liabilities (4,221,000) (243,000)
Change in fair value of derivative liability (597,000) 0
Change in fair value of convertible note receivable - Femasys 0 (912,000)
Change in fair value of warrant asset – Femasys 414,000 1,215,000
Change in fair value of investment – QCLS 5,550,000 2,839,000
Change in fair value of warrants - QCLS 3,181,000 4,832,000
Change in assets and liabilities:    
Increase in prepaid expenses and other current assets (123,509) (14,421)
Increase in accounts payable 119,433 66,005
Decrease in accrued expenses (177,175) (1,006,424)
Net cash and cash equivalents used in operating activities (780,894) (1,993,981)
Cash flows from financing activities:    
Payment of Series C convertible preferred stock dividends (83,399) 0
Net cash and cash equivalents used in financing activities (83,399) 0
Effect of currency rate exchange on cash and cash equivalents (615) 123
Net decrease in cash and cash equivalents (864,908) (1,993,858)
Cash and cash equivalents at beginning of the period 18,603,899 15,172,163
Cash and cash equivalents at end of the period 17,738,991 13,178,305
Supplemental disclosure of non-cash investing and financing activities:    
Accrual of Series C Convertible Preferred Stock dividends 83,399 0
Accretion of discounts to redemption value of Series C Preferred Stock $ 621,217 $ 0